RxDoctor Payments Data

Brenda Calhoun

Family · Columbus, OHNPI 1437450327

Payments from drug & device makers

$1,452in general payments, 2019–2025

Across 80 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$225
  • Novo Nordisk$130
  • Abbott$105
  • Boehringer Ingelheim$78
  • Pfizer$60
  • Neos Therapeutics, LP$55
  • plus $798 from 30 others

What the payments were for

  • Food & beverage$1,452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,452 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$21,323
Medicare patients
57
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$44,785
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$42,880
JardianceEmpagliflozin37$35,222
FarxigaDapagliflozin Propanediol32$28,877
TrulicityDulaglutide14$21,655
JanuviaSitagliptin Phosphate13$18,740
MounjaroTirzepatide13$13,405
SymbicortBudesonide/Formoterol Fumarate34$10,470
LinzessLinaclotide17$10,110
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$7,752
Incruse ElliptaUmeclidinium Bromide13$5,353
Breo ElliptaFluticasone/Vilanterol12$5,051
Atorvastatin Calcium324$4,092
Fluticasone-VilanterolFluticasone/Vilanterol11$2,908
Gabapentin81$2,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$52$61,03686 claims
Novo NordiskOzempic$130$44,78540 claims
AstraZenecaFarxiga, Symbicort$31$39,34766 claims
Boehringer IngelheimJardiance$78$35,22237 claims
Lilly USA, LLCTrulicity, Mounjaro$29$35,06027 claims
MerckJanuvia$43$18,74013 claims
AbbVieLinzess, Synthroid$225$11,06632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →